MA27933A1 - Inhibiteurs de l'activite de akt - Google Patents
Inhibiteurs de l'activite de aktInfo
- Publication number
- MA27933A1 MA27933A1 MA28757A MA28757A MA27933A1 MA 27933 A1 MA27933 A1 MA 27933A1 MA 28757 A MA28757 A MA 28757A MA 28757 A MA28757 A MA 28757A MA 27933 A1 MA27933 A1 MA 27933A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- akt activity
- activity
- akt
- imidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Inhibiteurs d'activité de Akt L'invention concerne des dérivés de 1H-imidazo [4, 5-c]-pyridine-2-yle, l'utilisation de ces composés comme inhibiteurs de l'activité de protéine-kinase B et dans le traitement du cancer et de l'arthrite.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49085103P | 2003-07-29 | 2003-07-29 | |
US49105503P | 2003-07-30 | 2003-07-30 | |
US49310103P | 2003-08-06 | 2003-08-06 | |
US49475203P | 2003-08-13 | 2003-08-13 | |
US50701403P | 2003-09-29 | 2003-09-29 | |
US53084703P | 2003-12-18 | 2003-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27933A1 true MA27933A1 (fr) | 2006-06-01 |
Family
ID=34120170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28757A MA27933A1 (fr) | 2003-07-29 | 2006-01-27 | Inhibiteurs de l'activite de akt |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080255143A1 (fr) |
EP (1) | EP1653961A4 (fr) |
JP (1) | JP2007500709A (fr) |
KR (1) | KR20060066714A (fr) |
AR (1) | AR045134A1 (fr) |
AU (1) | AU2004261214A1 (fr) |
BR (1) | BRPI0412993A (fr) |
CA (1) | CA2534038A1 (fr) |
CO (1) | CO5640140A2 (fr) |
IL (1) | IL173174A0 (fr) |
IS (1) | IS8322A (fr) |
MA (1) | MA27933A1 (fr) |
MX (1) | MXPA06001134A (fr) |
NO (1) | NO20060985L (fr) |
TW (1) | TW200523262A (fr) |
WO (1) | WO2005011700A1 (fr) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298311B1 (fr) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
CA2526617C (fr) | 2003-05-20 | 2015-04-28 | Bayer Pharmaceuticals Corporation | Diaryl-urees presentant une activite d'inhibition des kinases |
UA84156C2 (ru) | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний |
EP1689393A4 (fr) * | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
AR051202A1 (es) | 2004-09-20 | 2006-12-27 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
CN101083994A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途 |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
CA2580845A1 (fr) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques |
WO2006034315A2 (fr) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et utilisation de ceux-ci comme agents therapeutiques |
BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
EP1948185A4 (fr) * | 2005-11-10 | 2010-04-21 | Glaxosmithkline Llc | Inhibiteurs de l'activite de l'akt |
TW200736260A (en) * | 2005-11-10 | 2007-10-01 | Smithkline Beecham Corp | Inhibitors of Akt activity |
US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
US20080269131A1 (en) * | 2005-11-10 | 2008-10-30 | Smithkline Beecham Corporation | Inhibitors of Akt Activity |
US20080063637A1 (en) * | 2006-05-19 | 2008-03-13 | The Trustees Of Tufts College | Regulation of oncogenesis by Akt-specific isoforms |
WO2008063853A2 (fr) * | 2006-11-21 | 2008-05-29 | Smithkline Beecham (Cork) Limited | Procédé de traitement d'un cancer |
WO2008121685A1 (fr) * | 2007-03-28 | 2008-10-09 | Smithkline Beecham Corporation | Procédés d'utilisation pour inhibiteurs d'activité akt |
CN102027371A (zh) * | 2008-05-16 | 2011-04-20 | 塞尔卓姆股份公司 | Parp相互作用分子的鉴定方法和parp蛋白的纯化方法 |
RU2619463C2 (ru) * | 2009-12-30 | 2017-05-16 | Аркьюл, Инк. | Замещенные имидазопиридинил-аминопиридиновые соединения, полезные при лечении рака |
KR20130009978A (ko) * | 2010-02-26 | 2013-01-24 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 소자의 제조 방법 및 성막 장치 |
KR101419999B1 (ko) * | 2011-03-31 | 2014-08-12 | 건국대학교 산학협력단 | Akt 음성 조절제로서의 Hades의 용도 |
SG194048A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
JP6046710B2 (ja) | 2011-06-24 | 2016-12-21 | アーキュール,インコーポレイティド | 置換されたイミダゾピリジニル−アミノピリジン化合物 |
US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
CA2879454A1 (fr) | 2012-07-19 | 2014-01-23 | Drexel University | Nouveaux ligands du recepteur sigma et procedes de modulation de l'homeostase de proteine cellulaire a l'aide de ceux-ci |
JP2016512219A (ja) | 2013-03-15 | 2016-04-25 | シンジェンタ パーティシペーションズ アーゲー | 殺菌活性のあるイミダゾピリジン誘導体 |
PL3102555T3 (pl) * | 2014-02-05 | 2021-12-20 | VM Oncology LLC | Kompozycje związków i ich zastosowania |
WO2016038143A1 (fr) * | 2014-09-12 | 2016-03-17 | Syngenta Participations Ag | Composés 4-(imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine microbiocides comprenant un groupe oxime en position 7 |
RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
WO2019089902A1 (fr) | 2017-11-01 | 2019-05-09 | Drexel University | Composés, compositions et méthodes pour traiter des maladies |
EP3788038B1 (fr) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019217691A1 (fr) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3802537A1 (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
JP2022512706A (ja) | 2018-10-16 | 2022-02-07 | エフ.ホフマン-ラ ロシュ アーゲー | 眼科におけるAkt阻害剤の使用 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3117222A1 (fr) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
MA54547A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
ES2953821T3 (es) | 2018-12-20 | 2023-11-16 | Amgen Inc | Inhibidores de KIF18A |
PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
EP3972973A1 (fr) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Formes à l'état solide |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021026098A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
WO2021081212A1 (fr) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer |
IL292438A (en) | 2019-10-28 | 2022-06-01 | Merck Sharp & Dohme | Small molecules that inhibit the g12c mutant of kras |
US20230023023A1 (en) | 2019-10-31 | 2023-01-26 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
CA3159559A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
EP4054719A1 (fr) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
PE20230249A1 (es) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | Compuestos de heteroarilo biciclicos y usos de estos |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
WO2021097212A1 (fr) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthèse améliorée de composé inhibiteur de kras g12c |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
WO2021106231A1 (fr) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
BR112022010086A2 (pt) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | Dosagem do inibidor de shp2 e métodos de tratamento de câncer |
US20230181536A1 (en) | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
AU2021308045A1 (en) | 2020-07-15 | 2023-02-23 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2022235870A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras pour le traitement du cancer |
CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
EP4347041A1 (fr) | 2021-05-28 | 2024-04-10 | Taiho Pharmaceutical Co., Ltd. | Petites molécules inhibitrices de protéines mutées par kras |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2024081916A1 (fr) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281005A (en) * | 1979-03-05 | 1981-07-28 | Merck & Co., Inc. | Novel 2-pyridylimidazole compounds |
US6001866A (en) * | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
AU6966696A (en) * | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5972980A (en) * | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
BR9815170A (pt) * | 1997-12-12 | 2000-10-10 | Euro Celtique S A Luxembourg | "método de obter composto aplicável no tratamento de asma em mamìferos" |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6130333A (en) * | 1998-11-27 | 2000-10-10 | Monsanto Company | Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use |
ID30204A (id) * | 1999-12-27 | 2001-11-15 | Japan Tobacco Inc | Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat |
US6770666B2 (en) * | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Gsk-3의 억제제로서 유용한 헤테로아릴 화합물 |
GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
GB0206861D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Medicaments |
US7517887B2 (en) * | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
EP1670466A4 (fr) * | 2003-10-06 | 2007-04-25 | Glaxo Group Ltd | Preparation d'azabenzimidazoles trisubstitues en position 1,6,7 servant d'inhibiteurs des kinases |
WO2005037197A2 (fr) * | 2003-10-06 | 2005-04-28 | Glaxo Group Limited | Preparation d'azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases |
EP1689393A4 (fr) * | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases |
WO2005046678A1 (fr) * | 2003-11-07 | 2005-05-26 | Smithkline Beecham (Cork) Limited | Methode de traitement du cancer |
-
2004
- 2004-07-27 AR ARP040102668A patent/AR045134A1/es not_active Application Discontinuation
- 2004-07-27 TW TW093122340A patent/TW200523262A/zh unknown
- 2004-07-28 AU AU2004261214A patent/AU2004261214A1/en not_active Abandoned
- 2004-07-28 CA CA002534038A patent/CA2534038A1/fr not_active Abandoned
- 2004-07-28 US US10/565,329 patent/US20080255143A1/en not_active Abandoned
- 2004-07-28 WO PCT/US2004/024340 patent/WO2005011700A1/fr active Application Filing
- 2004-07-28 JP JP2006522030A patent/JP2007500709A/ja active Pending
- 2004-07-28 EP EP04779406A patent/EP1653961A4/fr not_active Withdrawn
- 2004-07-28 MX MXPA06001134A patent/MXPA06001134A/es unknown
- 2004-07-28 BR BRPI0412993-8A patent/BRPI0412993A/pt not_active IP Right Cessation
- 2004-07-28 KR KR1020067002022A patent/KR20060066714A/ko not_active Application Discontinuation
-
2006
- 2006-01-16 IL IL173174A patent/IL173174A0/en unknown
- 2006-01-26 CO CO06007246A patent/CO5640140A2/es not_active Application Discontinuation
- 2006-01-27 MA MA28757A patent/MA27933A1/fr unknown
- 2006-02-22 IS IS8322A patent/IS8322A/is unknown
- 2006-02-28 NO NO20060985A patent/NO20060985L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0412993A (pt) | 2006-10-03 |
AR045134A1 (es) | 2005-10-19 |
CA2534038A1 (fr) | 2005-02-10 |
EP1653961A4 (fr) | 2009-04-01 |
KR20060066714A (ko) | 2006-06-16 |
EP1653961A1 (fr) | 2006-05-10 |
IS8322A (is) | 2006-02-22 |
MXPA06001134A (es) | 2006-04-11 |
JP2007500709A (ja) | 2007-01-18 |
NO20060985L (no) | 2006-04-19 |
US20080255143A1 (en) | 2008-10-16 |
TW200523262A (en) | 2005-07-16 |
CO5640140A2 (es) | 2006-05-31 |
IL173174A0 (en) | 2006-06-11 |
WO2005011700A1 (fr) | 2005-02-10 |
AU2004261214A1 (en) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27933A1 (fr) | Inhibiteurs de l'activite de akt | |
MA29935B1 (fr) | Inhibiteurs de l'activite de akt | |
ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
MA31167B1 (fr) | Inhibiteurs de l'activite de akt | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
EP1673078A4 (fr) | Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer | |
NO20061194L (no) | Mitotiske kinesininbibitorer | |
EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
PA8501801A1 (es) | Inhibidores triciclicos de polimerasas (adp - polirribosas) | |
AP1498A (en) | Inhibitors of impdh enzyme. | |
WO2004087699A3 (fr) | Thiazoles utiles en tant qu'inhibiteurs des proteines kinases | |
WO2004087698A3 (fr) | Thiazoles utiles en tant qu'inhibiteurs de proteines kinases | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE301653T1 (de) | Pyrazolopyridine | |
EP1689713A4 (fr) | Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer | |
TW200716110A (en) | Inhibitors of AKT activity | |
MA31336B1 (fr) | Inhibiteurs de pi3k alpha a base de pyridopyrimidinone | |
DE60206198T2 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
ATE368040T1 (de) | Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren |